Shots: The P-III HAWK (6/3mg) & HARRIER (6mg) study assessing Beovu [q12w/q8w with the majority on q12w following the loading phase) vs aflibercept (2mg) in 1,800 patients with wet AMD […]readmore
Tags : Brolucizumab
Shots: The EU label update includes additional categorization of retinal vasculitis and/or retinal vascular occlusion, usually in the intraocular inflammation. The approval follows Novartis completion of safety review and initiation […]readmore
Shots: The EC’s approval is based on P-III HAWK (6/3mg) & HARRIER (6mg) study assessing Beovu [q12w/q8w with the majority on q12w following the loading phase) vs aflibercept 2 mg […]readmore
Shots: The approval is based on P-III HAWK (NCT02307682) & HARRIER (NCT02434328) studies involves assessing of Beovu (intravitreal injection), 6mg (HAWK and HARRIER) & 3mg (HAWK) vs Aflibercept (2mg) in […]readmore
Shots: The BLA submission is based on P-III HAWK and HARRIER study results assessing brolucizumab (3/6 mg, q12w/q8w) vs aflibercept in 1800 patients with neovascular age-related macular degeneration nAMD or […]readmore